Obstacles Facing Tuberculosis Treatment in Children from a Developing Country: a Hospital-based Study

Heda Melinda Nataprawira^1, and Nathania Wonoputri¹

¹Department of Child Health, Hasan Sadikin General Hospital-Universitas Padjadjaran, Bandung, Indonesia

Cite this paper:
Heda Melinda Nataprawira and Nathania Wonoputri. Obstacles Facing Tuberculosis Treatment in Children from a Developing Country: a Hospital-based Study. American Journal of Epidemiology and Infectious Disease. 2014; 2(1):8-12. doi: 10.12691/ajeid-2-1-2

Abstract

Background: Despite availability of antituberculosis treatment and application of directly observed treatment short-course (DOTS) strategy, loss to follow-up in tuberculosis (TB) treatment is still a problem in controlling TB, especially in TB high-burden countries. Methods: This retrospective survey study to determine the magnitude and factors influencing loss to follow-up TB treatment was conducted on 1,350 documented clinically diagnosed TB cases registered in pediatric DOTS registry from January 2009 to June 2012. We interviewed the parents of 102 identified loss to follow-up TB treatment children. Results: Of the 102 (8.2%) children identified as loss to follow-up TB treatment, five children had completed TB treatment at the nearest public health facility, concluding loss to follow-up rate 7.8%. Survey obtained showed that the most common problems encountered are financial (22.7%), time clash of working parents (16.5%), and far dwelling (16.5%). Far dwelling (p = 0.027) and drug formulations (p = 0.001) are the significant factors influencing loss to follow patients. Conclusions: Our study found that children with far dwelling to the health facility in order to take TB treatment and different drug formula are the significant factors influencing loss to follow-up patients.

Keywords:
loss to follow-up TB treatment children DOTS strategy

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Perez-Velez CM, Marais BJ, “Tuberculosis in children,” N Engl J Med, 367. 348-61. 2012.
[2]	Marais BJ, Pai M, “New approaches and emerging technologies in the diagnosis of childhood tuberculosis,” Paediatr Respir Rev, 8. 124-33. 2007.
[3]	Swaminathan S, Rekha B, “Pediatric tuberculosis: global overview and challenges,” Clin Infect Dis, 50. 184-94. 2010.
[4]	Sharma S, Sarin R, Khalid UK, Sharma PP, Behera D, “The DOTS strategy for treatment of paediatric pulmonary tuberculosis in South Delhi, India,” Int J Tuberc Lung Dis, 11(12). 74-80. 2007.
[5]	Phongsamart W, Kitai I, Gardam M, Wang J, Khan K, “ A population-based study of tuberculosis in children and adolescents in Ontario,” Pediatr Infect Dis J, 28. 416-9. 2009.
[6]	Sharma S, Sarin R, Khalid UK, Singla N, Sharma PP, Behera D, “Clinical profile and treatment outcome of tuberculosis lymphadenitis in children using DOTS strategy,” Indian J Tuberc, 57. 4-11. 2010.
[7]	Graham SM, Gie RP, Schaaf HS, Coulter JBS, Espinal MA, Beyers N, “Childhood tuberculosis: clinical research needs,” Int J Tuberc Lung Dis, 8(5). 648-57. 2004.
[8]	Oliveira VLS, Cunha AJLA, Alves R, “Tuberculosis treatment default among Brazilian children,” Int J Tuberc Lung Dis, 10(8). 864-69. 2006.
[9]	Harries AD, Hargreaves NJ, Graham SM, Mwansambo C, Kazembe P, Broadhead RL, et al., “Childhood tuberculosis in Malawi: nationwide case-finding and treatment outcomes,” Int J Tuberc Lung Dis, 6(5). 424-31. 2002.
[10]	Safdar N, “Diagnosis and outcome of childhood tuberculosis: implementing public health policy in three districts of Pakistan,” Int J Tuberc Lung Dis, 14(7). 872-77. 2010.
[11]	WHO, Global tuberculosis report 2012, WHO Press, Geneva, 2012.
[12]	Kruk ME, Schwalbe NR, Aguiar CA, “Timing of default from tuberculosis treatment: a systematic review,” Trop Med Int Health, 13(5). 703-12. 2008.
[13]	Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F, “Factors associated with default from treatment among tuberculosis patients in Nairobi province, Kenya: a case control study,” BMC Public Health, 11(696). 1-10. 2011.
[14]	Onkado A, Sugiyama T, Murakami K, Ishikawa N, Borgdoff M, Cleeff M, et al, “Informed patient consent for defaulter tracing: should we obtain it?” Int J Tuberc Lung Dis, 13(5). 551-5. 2009.
[15]	WHO. Definitions and reposrting framework for tuberculosis-2013 revision. WHO, Genewa, 2013.
[16]	Sharma SK, Chauhan LS. Operational issues, compliance and DOTS programme. In: Schaaf HS, Zumla A, (eds). Tuberculosis (a comprehensive clinical reference), Elsevier Saunders, London, 2009, 668-75.
[17]	Marais BJ, Gie RP, Schaaf HS, Beyers N, Donald PR, Starke JR, “Childhood pulmonary tuberculosis (old wisdom and new challenges),” Am J Respir Crit Care Med, 173. 1078-90. 2006.
[18]	Santha T, Garg R, Frieden TR, Chandrasekaran V, Subramani R, Gopi PG, et al, “Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS programme in Tiruvallur District, South India, 2000” Int J Tuberc Lung Dis, 6(9), 780-8. 2002.